Ramesh Patel, MD
Psychiatry · Riverside, CANPI 1912044520
Payments from drug & device makers
Across 709 payments — averaging $157.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$66K
- Alkermes, Inc.$27K
- Sunovion Pharmaceuticals Inc.$9K
- Johnson & Johnson$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$771
- plus $1000 from 6 others
What the payments were for
- Consulting fees$2,6802%
- Speaking & faculty fees$92,26083%
- Travel & lodging$1,6331%
- Food & beverage$14,74213%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 245 | $66,495 |
| Alkermes, Inc. | 115 | $26,929 |
| Sunovion Pharmaceuticals Inc. | 168 | $8,615 |
| Johnson & Johnson | 118 | $4,835 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $2,884 |
| Teva Pharmaceuticals USA, Inc. | 19 | $771 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $546 |
| Neurocrine Biosciences, Inc. | 2 | $280 |
| E.r. Squibb & Sons, L.L.C. | 3 | $78 |
| Boehringer Ingelheim | 1 | $40 |
| Lundbeck LLC | 2 | $38 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$99,024
- ABILIFY MAINTENA$40,494
- ARISTADA INITIO$24,756
- REXULTI$22,820
- ABILIFY ASIMTUFII$7,796
- LATUDA$5,253
- INVEGA SUSTENNA$2,158
- INVEGA TRINZA$1,478
- INGREZZA$280
- Austedo XR$125
- UZEDY$125
How this compares
$111,529 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 145 | $403,634 |
| Abilify MaintenaAripiprazole | 36 | $99,667 |
| Invega TrinzaPaliperidone Palmitate | 13 | $95,642 |
| AristadaAripiprazole Lauroxil | 33 | $86,114 |
| Abilify AsimtufiiAripiprazole | 13 | $73,609 |
| RexultiBrexpiprazole | 28 | $41,082 |
| UzedyRisperidone | 13 | $31,415 |
| Lurasidone Hcl | 85 | $18,095 |
| Paliperidone ErPaliperidone | 39 | $3,444 |
| Aripiprazole | 59 | $2,943 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $2,591 |
| Benztropine Mesylate | 190 | $1,790 |
| Divalproex Sodium ErDivalproex Sodium | 76 | $1,715 |
| Divalproex Sodium | 45 | $1,576 |
| Clozapine | 14 | $1,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $4,835 | $499,276158 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $66,495 | $214,35777 claims |
| Alkermes, Inc.Aristada | $26,929 | $86,11433 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $771 | $31,41513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Riverside
- Evagelos CoskinasRiverside$7.3M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.